| __timestamp | Neurocrine Biosciences, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 1271353000 |
| Thursday, January 1, 2015 | 81491000 | 1620577000 |
| Friday, January 1, 2016 | 94291000 | 2052295000 |
| Sunday, January 1, 2017 | 121827000 | 2075142000 |
| Monday, January 1, 2018 | 160524000 | 2186100000 |
| Tuesday, January 1, 2019 | 200000000 | 3036600000 |
| Wednesday, January 1, 2020 | 275000000 | 2735000000 |
| Friday, January 1, 2021 | 328100000 | 2908100000 |
| Saturday, January 1, 2022 | 463800000 | 3592500000 |
| Sunday, January 1, 2023 | 565000000 | 4439000000 |
| Monday, January 1, 2024 | 731100000 | 5132000000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Regeneron consistently outpaced Neurocrine, with its R&D expenses growing by approximately 250%, reaching a peak of $4.4 billion in 2023. In contrast, Neurocrine's R&D spending increased by nearly 1,100% over the same period, albeit from a much smaller base, culminating in $565 million in 2023. This disparity highlights Regeneron's robust financial capacity and strategic focus on large-scale innovation, while Neurocrine's rapid growth underscores its aggressive push to expand its research capabilities. As these companies continue to invest in R&D, their strategic choices will shape the future of biotech innovation.
Regeneron Pharmaceuticals, Inc. or argenx SE: Who Invests More in Innovation?
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Galapagos NV
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: GSK plc vs Neurocrine Biosciences, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc. Allocate Funds
Comparing Innovation Spending: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Research and Development: Comparing Key Metrics for Neurocrine Biosciences, Inc. and Incyte Corporation
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Veracyte, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xencor, Inc.
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.